

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Recombinant Anti-PD1 antibody [EPR20665]

RRID:AB_2941806

Type: Antibody

Proper Citation

Abcam Cat# ab214421, RRID:AB_2941806

Antibody Information

URL: http://antibodyregistry.org/AB_2941806

Proper Citation: Abcam Cat# ab214421, RRID:AB_2941806

Target Antigen: PD1

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IHC-P, ICC/IF

Antibody Name: Recombinant Anti-PD1 antibody [EPR20665]

Description: This recombinant monoclonal targets PD1

Target Organism: mouse

Clone ID: EPR20665

Antibody ID: AB_2941806

Vendor: Abcam

Catalog Number: ab214421

Record Creation Time: 20231110T031133+0000

Record Last Update: 20260901T044936+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-PD1 antibody [EPR20665].

No alerts have been found for Recombinant Anti-PD1 antibody [EPR20665].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Shang X, et al. (2026) Dual PD-1/IL-2R γ targeting restores CD8⁺ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. *Cell reports. Medicine*, 7(3), 102633.

Yang S, et al. (2026) Oat- β -glucan potentiates anti-PD-1 efficacy through *Faecalibacterium prausnitzii*-derived butyrate and indole-3-propionic acid. *Cell host & microbe*, 34(7), 1333.

Fehrenbach P, et al. (2026) Beyond the skin barrier: commensal *S. epidermidis* imprint systemic immunity to invasive biofilm infection. *bioRxiv : the preprint server for biology*.

Dong Z, et al. (2026) Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor. *Cell host & microbe*.

Mödl B, et al. (2026) TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis. *Cancer research*, 86(1), 80.

Zhou J, et al. (2026) Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinoma. *Cell host & microbe*, 34(4), 639.

Zhang M, et al. (2026) Microglia prune developing cortical blood vessels through PD-1 signaling. *Nature neuroscience*.

Xiao J, et al. (2025) Uridine depletion impairs CD8⁺ T cell antitumor activity through N-glycosylation. *Cell metabolism*.

Yang S, et al. (2025) LTA4H improves the tumor microenvironment and prevents HCC progression via targeting the HNRNPA1/LTBP1/TGF- β axis. *Cell reports. Medicine*, 6(3), 102000.

Ding CH, et al. (2025) PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma. *Cell death & disease*, 16(1), 158.

Wang X, et al. (2024) *Fusobacterium nucleatum* facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. *Cancer cell*, 42(10), 1729.

Liu L, et al. (2023) Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. *Cell reports. Medicine*, 4(10), 101206.